A new study shows that lecanemab, an amyloid-clearing Alzheimer’s therapy, does not improve the brain’s waste-removal network ...

Anavex Life Sciences (AVXL) stock falls as the company faces a potential failure to win EU approval for its Alzheimer’s ...

In a new study, scientists discovered two FDA-approved cancer drugs that could also be effective at combatting one well-known ...

Anavex Life Sciences ( ($AVXL) ) has issued an update. On November 14, 2025, Anavex Life Sciences announced that the Committee for Medicinal ...

The roadmap to fighting Alzheimer’s disease is a matter of updating government policy to match the current science.

Researchers found that lecanemab, the Alzheimer’s drug designed to clear amyloid-β plaques, does not improve the brain’s waste clearance system in the short term.

Mayo Clinic researchers have developed a new tool that can estimate a person's risk of developing memory and thinking ...

Health Canada recently approved lecanemab (brand name Leqembi®) to treat people with mild cognitive impairment or mild ...

Anavex Life Sciences faces regulatory setbacks, pipeline doubts, and dilution risks. Click here to read my latest analysis of ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

Japanese researchers found that lecanemab, an amyloid-clearing drug for Alzheimer’s, does not improve the brain’s waste clearance system in the short term. This implies that nerve damage and impaired ...

Anavex Life Sciences said European regulators informed it of a negative trend vote related to its application for its blarcamesine treatment of early Alzheimer's disease. The Committee for Medicinal ...